Regulatory Frameworks for 3d-Printed Pharmaceuticals: A Comparative Analysis of FDA and EMA
Keywords:
Additive manufacturing, Personalised medicine, Pharmaceutical regulation, Regulatory harmonisation, Three-dimensional printingAbstract
Three-dimensional (3D) printing has been accepted as an emerging technique in pharmaceutical development with potential for personalized medication, controlled drug release and customizable dose forms. However, its application in pharmaceutical production poses regulatory obstacles to product quality, process validation, and production consistency. This study will try to examine and compare the regulatory systems of the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) for 3D-printed pharmaceuticals. The research will concentrate on quality standards, regulatory submissions, approval procedures, and new regulatory aspects. A comparison analysis was undertaken based on official regulatory documents, international legislation, and published scientific research. The findings indicate that both organizations adhere to the established pharmaceutical regulatory standards, encompassing the assessment of final product quality, process validation, quality management, and Good Manufacturing Practice. The FDA's regulatory expertise is demonstrated by the approval of Spritam and the initiation of its Emerging Technology Program. The European Medicines Agency (EMA) established more specific Quality and GMP standards for 3D printing in its 2026 guidelines for solid oral dosage forms. The key issues include the defining of batches, reproducibility, integrity of digital data, variability of materials and processes, and customized and decentralized manufacturing. The study refers to the need for more explicit technology-oriented quality standards, efficient production and digital control, and improved regulatory alignment to promote the development of 3D-printed medications, for the safe, quality and welfare of patients.
Downloads
References
1. Alzhrani, R. F., Fitaihi, R. A., Majrashi, M. A., Zhang, Y., & Maniruzzaman, M. (2025). Toward a harmonized regulatory framework for 3D-printed pharmaceutical products: The role of critical feedstock materials and process parameters. Drug Delivery and Translational Research, 15, 4501–4518.
2. Aprecia Pharmaceuticals Company. (2016). Spritam (levetiracetam) tablets: Prescribing information.
3. Awad, A., Trenfield, S. J., Goyanes, A., Gaisford, S., & Basit, A. W. (2018). Reshaping drug development using 3D printing. Drug Discovery Today, 23(8), 1547–1555.
4. European Commission. (2020). EudraLex Volume 4: EU guidelines for good manufacturing practice for medicinal products.
5. European Medicines Agency. (2020a). Network strategy to 2025.
6. European Medicines Agency. (2020b). Regulatory science to 2025: Strategic reflection.
7. European Medicines Agency. (2021). Reflection paper on the use of innovative manufacturing technologies.
8. European Medicines Agency. (2022). Authorisation of medicines in the EU.
9. European Medicines Agency. (2024). Obtaining an EU marketing authorisation, step-by-step.
10. European Medicines Agency. (2026). Questions & answers on the implementation of 3DP technology (additive manufacturing technology) for solid oral dosage forms (EMA/CHMP/CVMP/QIG/GMP/QWP/55150/2026).
11. Goyanes, A., Buanz, A. B. M., Hatton, G. B., Gaisford, S., & Basit, A. W. (2015). 3D printing of medicines: Engineering novel oral devices with unique design and drug release characteristics. Molecular Pharmaceutics, 12(11), 4077–4084.
12. Goyanes, A., Allahham, N., Trenfield, S. J., Stoyanov, E., Gaisford, S., & Basit, A. W. (2019). Direct powder extrusion 3D printing: Fabrication of drug products using a novel single-step process. International Journal of Pharmaceutics, 567, 118471.
13. Ianno, V., Vurpillot, S., Prillieux, S., & Espeau, P. (2024). Pediatric formulations developed by extrusion-based 3D printing: From past discoveries to future prospects. Pharmaceutics, 16(4), 441.
14. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2004). M4(R4): Organisation of the common technical document for the registration of pharmaceuticals for human use.
15. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2008). ICH Q10: Pharmaceutical quality system.
16. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Q8(R2): Pharmaceutical development.
17. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2023). ICH Q9(R1): Quality risk management.
18. Jamróz, W., Szafraniec, J., Kurek, M., & Jachowicz, R. (2018). 3D printing in pharmaceutical and medical applications—Recent achievements and challenges. Pharmaceutical Research, 35(9), 176.
19. Khaled, S. A., Burley, J. C., Alexander, M. R., Yang, J., & Roberts, C. J. (2015). 3D printing of tablets containing multiple drugs with defined release profiles. International Journal of Pharmaceutics, 494(2), 643–650.
20. Mirza, M. A., & Iqbal, Z. (2018). 3D printing in pharmaceuticals: Regulatory perspective. Current Pharmaceutical Design, 24(42), 5081–5083.
21. Norman, J., Madurawe, R. D., Moore, C. M. V., Khan, M. A., & Khairuzzaman, A. (2017). A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Advanced Drug Delivery Reviews, 108, 39–50.
22. Parhi, R. (2021). 3D printing in pharmaceutical applications: Recent advances and regulatory perspectives. Journal of Drug Delivery Science and Technology, 64, 102508.
23. Trenfield, S. J., Awad, A., Goyanes, A., Gaisford, S., & Basit, A. W. (2018). 3D printing pharmaceuticals: Drug development to frontline care. Trends in Pharmacological Sciences, 39(5), 440–451.
24. U.S. Food and Drug Administration. (2015). Spritam (levetiracetam) tablets: Cross discipline team leader review.
25. U.S. Food and Drug Administration. (2017). Advancement of emerging technology applications for pharmaceutical innovation and modernization: Guidance for industry.
26. U.S. Food and Drug Administration. (2020). Current good manufacturing practice for finished pharmaceuticals (21 CFR Parts 210 and 211).
27. U.S. Food and Drug Administration. (2024). The FDA's drug review process: Ensuring drugs are safe and effective.
28. U.S. Food and Drug Administration. (2026a). Electronic Common Technical Document (eCTD).
29. U.S. Food and Drug Administration. (2026b). eCTD submission standards for eCTD v4.0 and regional M1.
30. Wang, S., Chen, X., Han, X., Hong, X., Li, X., Zhang, H., Li, M., Wang, Z., & Zheng, A. (2023). A review of 3D printing technology in pharmaceutics: Technology and applications, now and future. Pharmaceutics, 15(2), 416.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

.